Overexpression of human osteopontin increases cell proliferation and migration in human embryo kidney-293 cells

• Autorzy: Liu Y -J , Zhang D.-Q. , Sui X.-M. , Tian W.
• Języki publikacji: EN

Abstrakty

EN

Malignant tumors are characterized by dysregulated cell growth and the metastasis of secondary tumors. Numerous studies have documented that osteopontin (OPN) plays a key role in regulating tumor progression and metastasis. Here, we show that the overexpression of OPN in human embryo kidney-293 cells significantly increases both the level of cell proliferation, by provoking the G1/S transition, and the level of cell migration in vitro. These findings suggest that augmented OPN contributes to cell growth and motility. Inhibiting OPN or the pathway it stimulates may therefore represent a novel approach for the treatment of primary tumors and associated metastases.

Słowa kluczowe

EN

overexpression; man; osteopontin; cell proliferation; cell migration; proliferation; metastasis; human disease; patient; cancer; tumour; human embryo; kidney cell

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2009
• Tom: 14
• Numer: 4
• Opis fizyczny: p.670-678,fig.,ref.

Twórcy

autor

Liu Y -J

• Peking University, Beijing 100035, P.R.China

autor

Zhang D.-Q.

autor

Sui X.-M.

autor

Tian W.

Bibliografia

• 1. Ramaiah, S.K. and Rittling, S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol. Sci. 103 (2008) 4-13.
• 2. Rangaswami, H., Bulbule, A. and Kundu, G.C. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 16 (2006) 79-87.
• 3. Rittling, S.R. and Chambers, A.F. Role of osteopontin in tumour progression. Br. J. Cancer 90 (2004) 1877-1881.
• 4. Haqq, C., Nosrati, M., Sudilovsky, D., Crothers, J., Khodabakhsh, D., Pulliam, B.L., Federman, S., Miller, J.R., 3rd, Allen, R.E., Singer, M.I., Leong, S.P., Ljung, B.M., Sagebiel, R.W. and Kashani-Sabet, M. The gene expression signatures of melanoma progression. Proc. Natl. Acad. Sci. USA 102 (2005) 6092-6097.
• 5. Fedarko, N.S., Jain, A., Karadag, A., Van Eman, M.R. and Fisher, L.W. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res. 7 (2001) 4060-4066.
• 6. Wai, P.Y. and Kuo, P.C. The role of Osteopontin in tumor metastasis. J. Surg. Res. 121 (2004) 228-241.
• 7. Coppola, D., Szabo, M., Boulware, D., Muraca, P., Alsarraj, M., Chambers, A.F. and Yeatman, T.J. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin. Cancer Res. 10 (2004) 184-190.
• 8. Rodrigues, L.R., Teixeira, J.A., Schmitt, F.L., Paulsson, M. and LindmarkMansson, H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 1087-1097.
• 9. Suzuki, M., Mose, E., Galloy, C. and Tarin, D. Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts. Am. J. Pathol. 171 (2007) 682-692.
• 10. Standal, T., Borset, M. and Sundan, A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp. Oncol. 26 (2004) 179-184.
• 11. Furger, K.A., Menon, R.K., Tuck, A.B., Bramwell, V.H. and Chambers, A.F. The functional and clinical roles of osteopontin in cancer and metastasis. Curr. Mol. Med. 1 (2001) 621-632.
• 12. Chatterjee, S.K. and Zetter, B.R. Cancer biomarkers: knowing the present and predicting the future. Future Oncol. 1 (2005) 37-50.
• 13. El-Tanani, M.K., Campbell, F.C., Kurisetty, V., Jin, D., McCann, M. and Rudland, P.S. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 17 (2006) 463-474.
• 14. Johnston, N.I., Gunasekharan, V.K., Ravindranath, A., O'Connell, C., Johnston, P.G. and El-Tanani, M.K. Osteopontin as a target for cancer therapy. Front Biosci. 13 (2008) 4361-4372.
• 15. Mustafa, H., Strasser, B., Rauth, S., Irving, R.A. and Wark, K.L. Identification of a functional nuclear export signal in the green fluorescent protein asFP499. Biochem. Biophys. Res. Commun. 342 (2006) 1178-1182.
• 16. Elgavish, A., Prince, C., Chang, P.L., Lloyd, K., Lindsey, R. and Reed, R. Osteopontin stimulates a subpopulation of quiescent human prostate epithelial cells with high proliferative potential to divide in vitro. Prostate 35 (1998) 83-94.
• 17. Scatena, M., Almeida, M., Chaisson, M.L., Fausto, N., Nicosia, R.F. and Giachelli, C.M. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J. Cell Biol. 141 (1998) 1083-1093.
• 18. Chambers, A.F. and Tuck, A.B. Ras-responsive genes and tumor metastasis. Crit. Rev. Oncog. 4 (1993) 95-114.
• 19. Wai, P.Y., Mi, Z., Guo, H., Sarraf-Yazdi, S., Gao, C., Wei, J., Marroquin, C.E., Clary, B. and Kuo, P.C. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 26 (2005) 741-751.
• 20. Wu, Y., Denhardt, D.T. and Rittling, S.R. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br. J. Cancer 83 (2000) 156-163.
• 21. Denhardt, D. Osteopontin expression correlates with melanoma invasion. J. Invest. Dermatol. 124 (2005) xvi-xviii.
• 22. Geissinger, E., Weisser, C., Fischer, P., Schartl, M. and Wellbrock, C. Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. Cancer Res. 62 (2002) 4820-4828.
• 23. Bogenrieder, T. and Herlyn, M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22 (2003) 6524-6536.
• 24. Cook, A.C., Chambers, A.F., Turley, E.A. and Tuck, A.B. Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. J. Biol. Chem. 281 (2006) 24381-24389.